A European clinical trial found that sulthiame, a drug used in the treatment of epilepsy, reduced breathing interruptions.
Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...
Researchers found that the medication sulthiame reduced breathing interruptions and improved oxygen levels overnight in people with moderate to severe sleep apnea. The findings were published recently ...
InvestorsHub on MSN
Ovid Therapeutics secures $60M funding to advance epilepsy drug programs
Ovid Therapeutics Inc. (NASDAQ:OVID) said Wednesday it has raised $60 million through a private placement to support the ...
Clinical Trials Arena on MSN
Analysts tout market potential of Xenon’s epilepsy drug on Phase III win
Analysts are encouraged by azetukalner’s differentiated MoA and efficacy in epilepsy, as well as the lack of titration needed when prescribing the drug.
Findings published by The BMJ reinforce previous research linking use of the antiseizure drug valproate during pregnancy to neurodevelopmental disorders such as ADHD and autism in children, and ...
Nordot on MSN
This decades-old epilepsy drug cut sleep apnoea episodes by half in trials – could it soon replace CPAP?
An old epilepsy drug for sleep apnoea has sharply reduced night‑time breathing pauses in a major European trial. Could ...
Epileptic seizures alter sleep by prolonging the stage that's central to memory formation, potentially predisposing the brain ...
Ketogenic diet therapies, including the classic ketogenic diet, modified Atkins diet, and low glycaemic index treatment, have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results